top of page

NEWS

MAY 26, 2023

logo3_edited.png

RENATUS, CARBOHYDE SIGN MOU TO CO-DEVELOP CNS-TARGETED CHOLESTEROL MODULATORS

Renatus, Carbohyde sign MOU to co-develop novel cholesterol modulators for CNS disease applications.

APRIL 20, 2023

logo3_edited.png

RENATUS WAS SLECTED FOR THE SCALE-UP CHALLENGE LAB PROGRAM

Renatus was selected for the Scale-Up Challenge Lab program by Incheon Startup Park.

MARCH 17, 2023

logo3_edited.png

RENATUS HAS BEEN GRANTED A KEY PATENT FOR NOVEL CYCLODEXTRINS

Renatus has been granted a key patent for novel cyclodextrins for the treatment of cholesterol-driven diseases by Korea Intellectual Property Office (KIPO).

JANUARY 2, 2023

logo3_edited.png

RENATUS WAS SELECTED FOR THE HOSPITAL-BASED BUSINESS INNOVATION CENTER (HBIC) PROGRAM

Renatus was selected for the HBIC program by Korea Health Industry Development Institute (KHIDI).

JULY 25, 2022

logo3_edited.png

RENATUS WAS SELECTED FOR THE STARTUP-FOCUSED UNIVERSITY PROGRAM

Renatus was selected for the Startup-Focused University Program by Ministry of SMEs and Startups.

MAY 25, 2022

logo3_edited.png

RENATUS WAS SELECTED FOR THE SMART-X BIO PROGRAM

Renatus was selected for the Smart-X Bio program by Incheon Startup Park to support innovative bio startups.

MARCH 15, 2022

logo3_edited.png

RENATUS WAS SELECTED FOR THE HOSPITAL-BASED BUSINESS INNOVATION CENTER (HBIC) PROGRAM

Renatus was selected for the HBIC program by Korea Health Industry Development Institute (KHIDI).

JANUARY 23, 2022

logo3_edited.png

RENATUS LAUNCHES ITS OFFICIAL WEBSITE

Renatus, a pharma company pioneering next generation cyclodextrin-based therapies for the safe treatment of cholesterol-associated diseases, today opened its official website to public.

bottom of page